173959-12-1
Chemical Structure
IT9302
- CAS No.: 173959-12-1
- Formula:C48H82N14O13S2
- Molecular Weight:1127.38
InChIKey: GTORPNRZTBKYJB-AIEIIIEWSA-N
SMILES: O=C(N)C[C@@H](C(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCCCN)NC([C@H](CCSC)NC([C@H]([C@H](O)C)NC([C@H](CCSC)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](C)N)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IT9302 | 96.11% | IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
